Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations
Blood Research · 2026-12 · 61 (1)
DOI: 10.1007/s44313-026-00144-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Research, online erschienen am 03.06.2026. Verfasst von Yun-Tzu Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
Gilteritinib is an established FLT3 inhibitor used to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring FLT3 mutations. Prior studies have predominantly evaluated gilteritinib as a posttransplant maintenance therapy in patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) in complete remission. Nonetheless, evidence remains limited for patients who receive gilteritinib as salvage therapy in a relapsed or refractory setting, proceed to allo-HSCT, and subsequently continue gilteritinib maintenance. This real-world study aimed to address this knowledge gap in an Asian cohort. Method and Result Patients with FLT3 -mutated R/R AML received gilteritinib before transplantation, and those achieving engraftment without grade ≥ 2 acute graft-versus-host disease were offered posttransplant maintenance between days 30 and 90. The cohort (median age, 48 years; 92.0% FLT3 -ITD) achieved a complete response (CR) rate of 76.2%. At a median follow-up of 46.2 months, gilteritinib maintenance therapy was associated with longer relapse-free and overall survival and a significantly lower 1-year cumulative incidence of relapse. Exploratory measurable residual disease (MRD) subgroup analyses suggested a numerically greater survival difference in patients without flow cytometry-detectable MRD before or after transplantation; however, the findings are limited by the small sample size and lack of FLT3 -targeted next-generation sequencing-based MRD assessment.
Conclusion
Gilteritinib was generally well-tolerated, with no observed increase in cytomegalovirus (CMV)-related or graft-versus-host complications. This study provides real-world evidence in a clinically relevant scenario and supports the use of gilteritinib maintenance in patients with FLT3 -mutated AML who undergo transplantation during R/R disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
- Division of Hematological Oncology, Department of Internal Medicine, Chi-Mei Medical Center, Tainan, Taiwan.
- Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. xavierchtsai@ntu.edu.tw.
- Tai-Chen Cell Therapy Center, National Taiwan University, Taipei, Taiwan.
- Department of Hematology and Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Förderung
- National Science and Technology Council
- Ministry of Health and Welfare
Zitieren
APA
Lin, Y. T., Tsai, X. C., Tien, F. M., Kuo, Y. Y., Tseng, M. H., Liu, J. H., Ko, B. S., Cheng, C. L., Chou, S. C., Lin, M. E., Lin, C. C., Chuang, M. K., Yao, M., Hou, H. A., Chou, W. C., & Tien, H. F. (2026). Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00144-3
Vancouver
Lin YT, Tsai XC, Tien FM, Kuo YY, Tseng MH, Liu JH, et al. Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00144-3
BibTeX
@article{Lin2026,
author = {Lin, Yun-Tzu and Tsai, Xavier Cheng-Hong and Tien, Feng-Ming and Kuo, Yuan-Yeh and Tseng, Mei-Hsuan and Liu, Jia-Hau and Ko, Bor-Sheng and Cheng, Chieh-Lung and Chou, Sheng-Chieh and Lin, Ming-En and Lin, Chien-Chin and Chuang, Ming-Kai and Yao, Ming and Hou, Hsin-An and Chou, Wen-Chien and Tien, Hwei-Fang},
title = {Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations},
journal = {Blood Research},
year = {2026},
volume = {61},
number = {1},
doi = {10.1007/s44313-026-00144-3}
}
EUVIMED